Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor

Patent 5512593 Issued on April 30, 1996. Estimated Expiration Date:

April 30, 2013. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

Method for treating emotional numbness
Patent #: 5028612
Issued on: 07/02/1991
Inventor: Glover

Piperidine opioid antagonists Patent #: 5064834
Issued on: 11/12/1991
Inventor: Zimmerman, et al.

Inventor

Dante, Lee G.

Assignee

Nagle; John S.

Application

No. 031096 filed on 03/02/1993

US Classes:

514/410Polycyclo ring system having the five-membered hetero ring as one of the cyclos

Examiners

Primary: Cintins, Marianne M.
Assistant: MacMillan, Keith D.

Attorney, Agent or Firm

Nagle; John S.

International Class

A01N 043/38

Abstract

A new composition and method of treating depression includes administering to a depressed patient a pharmacologically effective dose of naloxone or naltrexone or their pharmacologically effective salts and esters in combination with at least one nontricyclic serotonin reuptake inhibitor antidepressant or their pharmacologically effective salts and esters. The patient may while undergoing antidepressant therapy be undergoing treatment with a benzodiazepine for anxiety.

Other References

American Psychiatric Assoc., Diagnostic & Statistical manual of Mental Disorders III APA, Wash., D.C. (1980), pp. 205-239
American Psychiatric Assoc., Diagnostic & Statistical Manual of Mental disorders IV APA, Wash., D.C. (1993), pp. 317-350 & 424-429
American Psychiatric Assoc., Practice Guidelines for Major Depressive Disorder in Adults, Am. J. Psychiatry, vol. 150:4, Apr. 1993 Suppl., pp. 1-26
Reist et al., A Controlled Trial of Desipramine in 18 Men With Posttraumatic Stress Disorder, Am. J. Psychiatry, vol. 146:4, Apr. 1989, pp. 513-516
Terenius et al., Naloxone Treatment in Depression: clinical Observations and Effect Psychopharmacolgy, vol. 54, 31-33 (1977)
Dave et al., Intravenous Naloxone Administration in Schizophrenia and Affective . . . Science, vol. 197, 74-76 (1977)
Cohen et al., High Dose Naloxone in Depression Biological Psychiatry, vol. 19, No. 6, 825-832 (1984)
Cohen et al., High Dose Naloxone Infusions in Normals Archives of General Psychiatry, vol. 40, 613-619 (1983)
Mendelson et al., Effects of Naltrexone On Mood And Neuroendocrine Function . . . Psychoneuroendocrinology, vol. 3, 231-236 (1979)
Hollister et al., Aversive Effects of Naltrexone In Subjects Not Dependent On . . . Drug and Alcohol Dependence, vol. 8, 37-41 (1981)
Crowley et al., Naltrexone-Induced Dysphoria in Former Opioid Addicts American J. of Psychiatry, vol. 142, No. 9, 1081-1084, (1985)
Greenstein et al., Naltrexone: A clinical Perspective J. of Clinical Psychiatry, vol. 45, No. 9, 26-28 (1984)
Whitehouse et al., Opioid Antagonists Overcome the Learned Helplessness Effect but Impair Competent Escape Behavior, Physiology & Behavior, vol. 30, 731-734 (1983)
Mucha, Ronald F., High-Dose Oral Naltrexone: Aversive Response in Drug Naive Rat Biological Psychiatry, vol. 27, 543-545 (1990)
Devoize et al., Influence of Naloxone on Antidepressant Drug Effects in the Forced Swimming Test in Mice, Psychopharmacology, vol. 84, 71-75 (1984